|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for triple hit lymphomas, and an expanding literature exists regarding predictive biomarkers and therapeutic regimens.
|
30043475 |
2018 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Some cytokines and proteins associated with cell survival and proliferation, such as BAFF, APRIL, IL6 and BCL2, have been found to be elevated both in SLE and lymphoma.
|
30458319 |
2018 |
|
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Double-hit lymphoma (DHL) is defined as lymphoma with concurrent BCL2 and MYC translocations.
|
29310838 |
2018 |
|
Lymphoma
|
0.500 |
AlteredExpression
|
group |
BEFREE |
The mRNA and protein expression levels of B cell leukemia/lymphoma (Bcl‑2), Bcl‑2 associated X (Bax), cyclin dependent kinase 4 (CDK4), cyclin D1 and p21 were evaluated using reverse transcription‑polymerase chain reaction and western blot analysis, respectively.
|
29115462 |
2018 |
|
Lymphoma
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Radiotherapy is a rational candidate for combining with BCL-2 inhibition, as DNA damage caused by radiotherapy increases the activity of pro-apoptotic BCL-2 pathway proteins, and lymphomas are exquisitely sensitive to radiation.
|
28566329 |
2017 |
|
Lymphoma
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Moreover, CCl4-induced apoptosis in the mouse liver was inhibited by hSAP, as measured by terminal-deoxynucleotidyl transferase mediated nick-end labeling (TUNEL) assay and cleaved caspase-3 expression. hSAP significantly restored the expression of B cell lymphoma/leukemia (Bcl)-2 and suppressed the expression of Bcl-2-associated X protein (Bax) in vivo.
|
28627620 |
2017 |
|
Lymphoma
|
0.500 |
AlteredExpression
|
group |
BEFREE |
In order to gain a more comprehensive insight into the nature of venetoclax resistance mechanisms, we evaluated the changes in the BCL-2 family members at the genetic and expression levels in seven different venetoclax-resistant derived leukemia and lymphoma cell lines.
|
28578655 |
2017 |
|
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
There were 47 DTHLs, 36 cases with MYC and BCL2 and/or BCL6 extra signals (ES) and/or rearrangements (ES group, excludes DTHLs), 9 with MYC rearrangements only (single-hit lymphoma), and 95 with no MYC abnormalities (NM).
|
28614202 |
2017 |
|
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
In this review, we summarize two sessions dedicated to "high-grade B cell lymphomas, with MYC and BCL2 and/or BCL6 rearrangements (so-called double/triple-hit lymphomas)" and "high-grade B cell lymphomas, NOS" as defined in the 2016 update of the WHO lymphoma classification, Burkitt lymphoma and related neoplasms, and terminally differentiated aggressive B cell lymphomas.
|
28844114 |
2017 |
|
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma.
|
27717585 |
2017 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
The B-cell lymphoma 2 (BCL2) family of proteins comprise key regulators of apoptosis and are implicated in the pathogenesis of many malignancies, including lymphomas and leukaemias.
|
28449207 |
2017 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Our results suggest BCLW may be equally as important in lymphomagenesis as BCL2 and that targeting BCLW in lymphomas should be considered.<i></i>.
|
28855351 |
2017 |
|
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Functional Implications of the spectrum of BCL2 mutations in Lymphoma.
|
27543313 |
2017 |
|
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Lymphoma viability remained unaffected by the genetic deletion or pharmacological inhibition of all alternative BCL-2 family members.
|
27055871 |
2016 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
However BCL6 also directly represses several DLBCL oncogenes such as BCL2 and BCL-XL that promote lymphoma survival.
|
26657288 |
2016 |
|
Lymphoma
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Eμ-Myc lymphomas engineered to express activated Nras upregulated BCL-2 and acquired a JQ1 resistance phenotype.
|
27406984 |
2016 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Indeed, previous studies using gene-targeted mice revealed that BCL-XL, but surprisingly not BCL-2, is critical for the development of c-MYC-induced pre-B/B lymphomas.
|
26962682 |
2016 |
|
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Double- and triple-hit lymphomas (DHL/THL) are aggressive B-cell neoplasms characterized by translocation of MYC with concurrent BCL2 and/or BCL6 translocation.
|
26892631 |
2016 |
|
Lymphoma
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Most of the refractory patients exhibit double-hit lymphoma (MYC-BCL2 rearrangement) or double-protein-expression lymphoma (MYC-BCL2 hyperexpression) which have a more aggressive clinical picture.
|
27913503 |
2016 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Interestingly, the histiocytic tumor component has been shown to harbor BCL2 gene translocations that are identical to those found in the lymphoma.
|
27134111 |
2016 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
The anti-apoptotic BCL-2 is classified as an oncogene, as damage to the BCL-2 gene has been shown to cause a number of cancers, including lymphoma.
|
27043233 |
2016 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
More recently, MYC rearrangement with multiple copies/gain of BCL2 or multiple copies/gain of MYC with a BCL2 rearrangement have been described and exhibit a very similar clinical course to conventional double-hit lymphomas.
|
27391453 |
2016 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
He trained in oncology at St Bartholomew's Hospital, London, where he was an Imperial Cancer Research Fund (ICRF) Clinical Research Fellow and completed his doctoral research on the Bcl-2 gene, its potential as a therapeutic target in lymphoma and the effects of CD40 ligation on the B-cell surface.
|
26616222 |
2016 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Moreover, genetic ablation of Kmt2d in mice overexpressing Bcl2 increases the incidence of GC-derived lymphomas resembling human tumors.
|
26366712 |
2015 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
The target genes of miRNA-342 such as B-cell CLL/lymphoma 2 (BCL2) were mainly enriched in the biological process related to cellular metabolic process and Disease Ontology terms of lymphoma.
|
25908172 |
2015 |